Hormone therapy linked to more frequent and longer-lasting migraines - News-Medical
This story deserves to be shared
Send it to someone who'd care, or post it on your networks.
Migraines are estimated to affect 10% to 29% of women during the menopause transition, when migraines often worsen and become more frequent, especially during perimenopause. This is due to unpredictable estrogen drops. A new study suggests postmenopausal women using hormone therapy will experience more frequent, longer-lasting migraines. Results of the study will be presented at the 2026 Annual Meeting of The Menopause Society in San Diego October 20-24, 2026.
Hormone therapy has proven to be successful in managing a wide array of bothersome menopause symptoms, especially hot flashes. A challenge, however, is that fluctuations in estrogen levels may influence migraines.
This article is an excerpt. To read the full content, visit the original source. News-Medical
Related articles
Ontario teens see sharp rise in depression and anxiety, worst among frequent cannabis users - Faculty of Health Sciences - McMaster University
Estrogen-only hormone therapy tied to lower dementia risk - Harvard Health
Use of estrogen-only hormone therapy by menopausal women may significantly lower their odds of developing Alzheimer’s-related brain changes or being diagnosed with dementia, according to a study published Sept. 8, 2026, in Neurology. Researchers analyzed two databases involving more than 20,000 women over age 50, comparing those who had reported estrogen-only hormone therapy use with women who didn’t use hormone therapy. (While the study didn’t explicitly state that the estrogen users had prior hysterectomies, estrogen-only therapy is advised only for women without a uterus. Progesterone is typically added to hormone therapy for women with a uterus to protect the uterus from changes in its lining that can lead to cancer.)
Innovative magnetic anastomosis enables immediate liver transplantation without cold preservation - Nature
Hang Liu1, Peng Liu3, Jiawei Yu1, Qiang Lu2, Yerong Qian1, Junxi Xiang1, Aihua Shi4, Shasha Wei4, Yi Lv1,3,4 & … Lifei Yang3,4 We’re sharing this article early to provide faster access to peer-reviewed, accepted research. It is citable and carries a permanent DOI. This version is subject to further edits and will be replaced automatically by the final Version of Record. All legal disclaimers apply.
Changing the COPD Narrative: Interview with David Mannino - EMJ
David Mannino | Professor, University of Kentucky College of Medicine, Lexington, USA; Chief Medical Officer, COPD Foundation Could you tell us what first drew you to respiratory medicine and COPD, and how this interest has developed throughout your career?
0 comments
No comments yet. Be the first to share your thoughts!